Search review questions

Neurological status at 1 to 2 years Percentage of participants with unchanged or improved neurological status · patients with single‐level cervical degenerative disc disease

Global health status at 1 to 2 years SF36‐PCS · patients with single‐level cervical degenerative disc disease

Global health status at 1 to 2 years SF36‐MCS · patients with single‐level cervical degenerative disc disease

All‐cause study withdrawal Investigator‐recorded · patients with allergic rhinitis1

Change in allergic rhinitis daily symptom score during the grass pollen season Each daily symptom score was the summation of (i) runny nose score, (ii) itchy nose score and (iii) sneezing score (each of these scores self recorded on a severity sca... · patients with allergic rhinitis1

Percentage of well days during the grass pollen season Well days were those days with a symptom score of less than or equal to 2, and no use of rescue medication Scale from: 0 to 100 · patients with allergic rhinitis1

Total quality of life score over 12 weeks Assessed as the total score over the entire 12‐week study period in the Juniper RQLQ, i.e. a patient‐specific test instrument derived from 28 questions drawn from 7 dimensions (sleep, non‐hay fever symptom... · patients with allergic rhinitis1

Percentage of days requiring rescue medication (i.e. as tablets) during the grass pollen season Self recorded each day4 Scale from: 0 to 100 · patients with allergic rhinitis1

Hospitalisation due to any adverse event Investigator‐assessed · patients with allergic rhinitis1

Any gastrointestinal adverse event Self recorded · patients with allergic rhinitis1

"Substantial" benefit At least 50% reduction in pain or equivalent · painful diabetic neuropathy

"Moderate" benefit At least 30% reduction in pain · painful diabetic neuropathy

Proportion below 30/100 mm on VAS · painful diabetic neuropathy

Patient global impression much or very much improved · painful diabetic neuropathy

Quality of life measure · painful diabetic neuropathy

Adverse event withdrawals · painful diabetic neuropathy

Serious adverse events · painful diabetic neuropathy

Death · painful diabetic neuropathy

Mortality (median 3 years) · patients with primary CNS lymphoma

Progression/relapse (median 3 years) · patients with primary CNS lymphoma

Treatment‐related mortality · patients with primary CNS lymphoma

Serious adverse events · patients with primary CNS lymphoma

Infections (grade 3 to 4) · patients with primary CNS lymphoma

Morbidity · patients with type 2 diabetes mellitus

Mortality · patients with type 2 diabetes mellitus

Health‐related quality of life · patients with type 2 diabetes mellitus

Functional outcomes · patients with type 2 diabetes mellitus

Costs · patients with type 2 diabetes mellitus

Adverse events (all adverse events) · patients with type 2 diabetes mellitus

HbA1c change from baseline to end point (%) ( · patients with type 2 diabetes mellitus

Utilisation of research (Thailand) (for six obstetric practices: social support during labour, magnesium sulphate for eclampsia, corticosteroids to women with preterm birth, selective episiotomy, antibiotic use at caesarean section and vacuum extr... · Healthcare decision makers, health system managers or policy makers

Utilisation of research (Mexico) (for six obstetric practices: social support during labour, magnesium sulphate for eclampsia, corticosteroids to women with preterm birth, selective episiotomy, antibiotic use at caesarean section and vacuum extrac... · Healthcare decision makers, health system managers or policy makers

Utilisation of research (4 obstetric practices: use of polyglycolic acid sutures, ventouse for instrumental delivery, prophylactic antibiotics in caesarean section, and prophylactic corticosteroids in preterm deliveries).2 · Healthcare decision makers, health system managers or policy makers

International Index of Erectile Function questionnaire 31 · patients with erectile dysfunction in patients with multiple sclerosis

International Index of Erectile Function questionnaire 41 · patients with erectile dysfunction in patients with multiple sclerosis

Sexual Encounter Profile questions 2 · patients with erectile dysfunction in patients with multiple sclerosis

Sexual Encounter Profile questions 3 · patients with erectile dysfunction in patients with multiple sclerosis

Global Assessment Question · patients with erectile dysfunction in patients with multiple sclerosis

Full desensitization to milk · patients with milk allergy

Short‐term overall improvement ‐ not measured · people with carpal tunnel syndrome

Adverse effects ‐ not measured · people with carpal tunnel syndrome

Short‐term improvement in CTS symptoms (pain) (3 months or less) ‐ At end of 12 weeks treatment (Protouch Keyboard) Scale: 0 to 10 · people with carpal tunnel syndrome

Short‐term improvement in functional ability (3 months or less) (Protouch Keyboard) Scale: 13 to 65 · people with carpal tunnel syndrome

Long‐term improvement in CTS symptoms (pain ) from baseline to end of 6 months treatment (Apple Adjustable Keyboard) Scale: 0 to 10 · people with carpal tunnel syndrome

Long‐term improvement in functional ability (> 3 months) ‐ not measured · people with carpal tunnel syndrome

Adherence ‐ not measured · patients with Improving outcomes in youth living with HIV

Mortality ‐ not measured · patients with Improving outcomes in youth living with HIV

Quality of life ‐ not measured · patients with Improving outcomes in youth living with HIV

Log 10 Viral load at 6 months · patients with Improving outcomes in youth living with HIV

Retention in care Number attending last · patients with Improving outcomes in youth living with HIV